<DOC>
	<DOCNO>NCT01397175</DOCNO>
	<brief_summary>The primary objective study compare rate device-oriented composite consist cardiac death , myocardial infarction clearly attributable nontarget vessel , clinically indicate target lesion revascularization among patient treat EES , ZES-R , BES 24-month clinical follow-up post-index procedure . Trial end point summarize Table I . The hypothesis BES equivalent EES BES equivalent ZES-R primary end point .</brief_summary>
	<brief_title>BES , EES , ZES-R Real World Practice</brief_title>
	<detailed_description>Previous randomize trial show superior efficacy drug-eluting stent ( DES ) , sirolimus-eluting stent ( SES , CYPHER , Cordis , US ) , paclitaxel-eluting stent ( PES , TAXUS , Boston Scientific , US ) , zotarolimus-eluting stent ( ZES , Endeavor , Medtronic , US ) compare bare metal stent ( BMS ) reduce neointimal hyperplasia , late luminal loss , angiographic restenosis lead decreased target lesion revascularization . Unfortunately , restenosis still occur late stent thrombosis develop delay endoluminal healing chronic inflammation.Accordingly , development new DES require improve efficacy reduce revascularization safety reduce risk stent thrombosis . With improvement polymer , drug , platform , 2nd generation DES , include everolimus-eluting stent ( EES , Xience V Xience Prime , Abbott , USA ) , zotarolimus-eluting stent biolinx polymer ( ZES-R , Endeavor Resolute Endeavor Resolute Integrity , Medtronic , USA ) , biolimus-eluting stent ( BES , BioMatrix Biomatrix Flex , Biosensors , USA ) , show superior non-inferior safety efficacy trial compare 1st generation DES . However , difficult know difference efficacy safety EES , ZES-R , BES , real world practice due lack data compare three 2nd generation DES directly . This study provide evidence CHOICE stent physician treat patient percutaneous coronary intervention .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria Age &gt; 19 year Subject able verbally confirm understand risk , benefit treatment alternative receive drugeluting stent ( ) he/she his/her legally authorize representative provide write informed consent prior study related procedure Subject must significant stenosis ( &gt; 50 % visual estimate ) native instent coronary artery Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , acute myocardial infarction , positive functional study reversible change ECG consistent ischemia ) . In subject coronary artery stenosis &gt; 75 % , evidence myocardial ischemia document Exclusion Criteria Subject know hypersensitivity contraindication follow medication : heparin , aspirin , clopidogrel , prasugrel , ticagrelor , biolimus A9 , everolimus , zotarolimus , stainless steel , cobalt chromium , contrast medium ( Patients document sensitivity contrast medium , effectively premedicated steroid diphenhydramine may enrol . However , true anaphylaxis prior contrast medium enrol . ) Subject use systemic ( intravenous ) biolimus A9 , everolimus zotarolimus within 12 month . Female subject childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study Subject plan elective surgical procedure would necessitate interruption antiplatelet first 12 month post enrollment Subject noncardiac comorbid condition life expectancy &lt; 2 year may result protocol noncompliance ( per site investigator 's medical judgment ) Subject cardiogenic shock presentation Subject actively participate another drug device investigational study , complete primary end point followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Drug-eluting stent</keyword>
</DOC>